Pappas Capital

We are excited to share that we’ve raised $115 million in Series C financing to advance GLM101, the first disease-modifying therapy in development for PMM2-CDG, into a Phase 2b trial. This milestone reflects the strength of our science, the dedication of our team, and the deep unmet need in PMM2-CDG. We are grateful to our new and existing investors for their support and shared commitment to patients and families who have long awaited a therapeutic breakthrough. Thank you to CTI Life Sciences Fund, funds managed by abrdn Inc., Advent Life Sciences, Novo Holdings, Sanofi Ventures, Abingworth, RiverVest Venture Partners, Sanderling Ventures, Chiesi Ventures, Remiges Ventures, and Asahi Kasei Ventures. Read the release for more: https://lnkd.in/g7rhJzRy #CDGresearch #RareDisease #RareDiseases #PMM2CDG #clinicaltrials

🙋♀️ Help us! We had a preview of some of the conversation planned for “The State of Venture Capital Funding” panel for Raleigh-Durham Startup Week and let me tell you, it’s going to be great. But we want to hear from you! Comment below which questions we should add to this incredible panel, and feel free to add a like or “here, here!” to the ones you agree with. Here’s a few directions we could take the conversation - which ones resonate with you? 1️⃣ What investment trends are we seeing right now, and how can startup leaders leverage those?  2️⃣ Will I (a startup leader) lose control when I partner with investors?  3️⃣ What do investors wish startup leaders knew before they walked through their door?  4️⃣ What else do investors bring to the table besides money?  5️⃣ What makes the Triangle an exciting place for people funding and building businesses right now? All are welcome to join this panel discussion, you do not need to be a LiLa member.  Register for the event today at https://lnkd.in/dbnJ-ava #WomenInvesting #VentureCapital #RDSW #LiLa #Startup #NorthCarolina #Raleigh #Durham 

“CED exists to create spaces for people like you to make the magic happen.” - Kelly Rowell kicking off the Strength in Numbers S.I.N. mixer at #VentureConnect2025 Excited to hear from a panel of some of the Triangles most impressive female founders, funders, operators, and supporters who are showing up for their peers and the next generation of women in entrepreneurship. Elizabeth Kelly, Susan Wall, Zakiya Alta Lee, MBA, Kelli Luginbuhl, and Liz Turpin, PhD, MBA

On the heels of Rare Disease Day we are excited to announce the dosing with #leriglitazone of the first girl with Rett syndrome, a devastating rare CNS disease. At Minoryx Therapeutics we are very encouraged by the recent positive results of leriglitazone in boys with #cALD and we are now expanding into additional orphan CNS indications with high unmet medical need. 🔬 Want to learn more? Read the interview at Inside Precision Medicine: https://lnkd.in/dbCj2nmS https://lnkd.in/dMhhZ2zW

In a panel discussion at the Emerging Company Forum, industry leaders from across North Carolina's life sciences ecosystem shared insights on the current investment trends, challenges, and opportunities facing early-stage companies in the state. The panel, moderated by Drew Cutshaw, M.D., principal and medical officer at Pappas Capital, featured a diverse group of experts, including - David Adair MD, co-founder and managing director, Solas BioVentures; - John Landers, director of finance, 2ndF;  - Jimmy Melton, co-founder and general partner, Cape Fear BioCapital;  - Norman Sharpless, M.D., co-founder and managing director, Jupiter BioVentures; and  - Kseniya Simpson, PhD, principal, Hatteras Venture Partners. The event was sponsored by EquipNet, @Incubate, Matica Biotechnology, Inc., Safety Partners and Smith Anderson. The discussion began with an overview of the life sciences investment landscape over the past year. Key points covered by the discussion included the challenges of raising early-stage funding, with series A prices doubling and consolidation among venture groups. The panelists emphasized the importance of commercial viability, early-stage planning and leveraging nondilutive funding like SBIR grants. They highlighted the need for a clear lead program, effective commercial analysis and understanding payer dynamics. The discussion also covered the role of family offices and the importance of building a strong, cohesive team and culture. https://lnkd.in/entGZzfT